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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYAdult stem cells and tumor-initiating cells (TICs) often employ different mechanisms of DNA damage response (DDR) as compared to
other tissue cell types. However, little is known about how mammary stem cells (MaSCs) and mammary TICs respond to DNA damage.
Using the mouse mammary gland and syngeneic p53-null tumors as models, we investigated the molecular and physiological conse-
quences of DNA damage in wild-type MaSCs, p53-null MaSCs, and p53-null TICs. We showed that wild-type MaSCs and basal cells
are more resistant to apoptosis and exhibit increased non-homologous end joining (NHEJ) activity. Loss of p53 in mammary epithelium
affected both cell-cycle regulation and DNA repair efficiency. In p53-null tumors, we showed that TICs are more resistant to ionizing
radiation (IR) due to decreased apoptosis, elevated NHEJ activity, and more-rapid DNA repair. These results have important implications
for understanding DDR mechanisms involved in both tumorigenesis and therapy resistance.INTRODUCTION
DNA damage may occur at a rate of 100,000 lesions per cell
per day due to internal and external insults (Hoeijmakers,
2009). Thanks to evolution, mammalian cells employ a
sophisticated and highly conserved DNA damage response
(DDR), which regulates cell cycle, damage repair, gene
expression, and, alternatively, apoptosis or senescence
(Harper and Elledge, 2007) to protect genome integrity
and prevent mutations. Among all kinds of DNA damage,
double-strand breaks (DSBs) are probably the most delete-
rious type of lesion, which is repaired through either the
homologous recombination (HR) or non-homologous end
joining (NHEJ) pathways (Khanna and Jackson, 2001).
DDR mechanisms are especially important for long-lived
tissue stem cells because they may accumulate more muta-
tions throughout their lifetime. Indeed, a recent study
showed that the total number of lifetime stem cell divisions
is highly correlated with cancer risk in a particular tissue
(Tomasetti and Vogelstein, 2015), further suggesting the
importance of maintaining genome integrity in stem cells.
Previous studies have shown that mouse hair follicle bulge
stem cells and hematopoietic stem cells exhibit increased
NHEJ activity and decreased apoptosis, resulting in their
resistance to ionizing radiation (IR) (Mohrin et al., 2010;
Sotiropoulou et al., 2010). However, little is known about
howmammary stem cells (MaSCs) respond to IR treatment.
The mammary epithelium is composed of basal and
luminal cell compartments. Although the existence and378 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Aprecise localization of bipotent MaSCs, which can give
rise to both basal and luminal cells, are still controversial,
most evidence suggests that MaSCs reside in the basal
compartment (Rios et al., 2014; Shackleton et al., 2006;
Stingl et al., 2006), and exhibit properties of myoepithelial
cells (Prater et al., 2014), a cell type predominant in basal
compartment. MaSCs can be further enriched using fluo-
rescence-activated cell sorting (FACS) with the cell surface
markers CD24 and either CD49f or CD29 (Shackleton
et al., 2006; Stingl et al., 2006). MaSCs play a critical role
in ensuring mammary gland homeostasis during puberty,
pregnancy, lactation, and involution (Visvader and Stingl,
2014). Hence, it is important to understand how MaSCs
maintain their genome integrity and how they react to
DNA damage. In addition, mutation or loss of function of
p53, a tumor suppressor gene that plays a major role in
DDR (Meek, 2009), is correlated not only with mammary
tumorigenesis but also with poor prognosis and treatment
response in breast cancer (Bergh et al., 1995; Berns et al.,
2000; Gasco et al., 2002; Sørlie et al., 2001). Therefore, dis-
secting the effects of p53 loss on DDR in mammary epi-
thelium, especially in MaSCs, is particularly important for
understanding breast cancer tumorigenesis.
In previous tumor studies, we have used a p53-null syn-
geneic mouse model to mimic p53 loss of function in
human breast cancer. This model was developed by trans-
planting p53-null mammary epithelium into the cleared
mammary fat pads of wild-type, syngeneic Balb/c-recipient
mice, resulting in spontaneous tumor development (Jerryuthors
et al., 2000). Previously, we demonstrated that this tumor
model mimics several of the different subtypes known to
occur in human breast cancer (Herschkowitz et al., 2012;
Zhang et al., 2008). Using this tumor model, we have iden-
tified tumor-initiating cells (TICs), also often referred to as
tumor-propagating or cancer stem cells, based upon their
expression of the cell surface markers CD24 and CD29,
andwe further demonstrated that these TICs aremore resis-
tant to IR (Zhang et al., 2008, 2010). However, similar to
several other studies demonstrating that TICs from mam-
mary tumors are more resistant to conventional therapies
(Creighton et al., 2009; Diehn et al., 2009; Li et al., 2008),
the DDR mechanisms underlying this therapeutic resis-
tance are still largely unknown.
In this study, we comprehensively analyzed DDR mech-
anisms in stem cells and non-stem cells from wild-type
and p53-null mammary epithelium and from p53-null tu-
mors. We demonstrated that wild-type MaSCs and basal
cells exhibited increased NHEJ activity and resistance to
apoptosis as compared to luminal cells. MaSCs also ex-
hibited increased G2 arrest after IR treatment. Loss of p53
in the mammary gland disrupted not only G1 cell-cycle
arrest, damage-induced quiescence, but also DNA repair
efficiency. Importantly, p53-null TICs exhibited mixed
characteristics of wild-type and p53-null MaSCs, including
decreased apoptosis, elevated NHEJ activity, and more-
rapid DNA repair, but lacked the cell-cycle arrest and quies-
cence following DNA damage. These results suggest that
inhibition of survival or the NHEJ pathway could offer
novel treatment options to selectively sensitize TICs to IR
treatment.RESULTS
Wild-Type MaSCs Are More Resistant to DNA
Damage-Induced Apoptosis
To study the effects of DNA damage on apoptosis in
different mammary epithelial cell compartments, 5- to 6-
week-old virgin mice were treated with or without 6 Gy
whole-body IR. Freshly dissociated mammary epithelial
cells (MECs) were then stained with the cell-surface mar-
kers CD24 and CD49f, the apoptosis marker annexin V,
and the dead cell marker Sytox Red, followed by flow
cytometry analysis (Figure S1A). MaSCs, basal cells, and
luminal cells were enriched in the LinCD49fhighCD24+,
LinCD49fhighCD24low, and LinCD49flowCD24+ subpop-
ulations, respectively. Apoptotic cells were represented by
annexin-V-positive and Sytox-Red-negative cells (Figures
1A and S1A). In the absence of IR treatment, MaSCs and
basal cells exhibited significantly decreased annexin V pos-
itivity as compared to untreated luminal cells, indicating
they are intrinsically more resistant to apoptosis (Fig-Stem Cellure 1B). To understand the kinetics of apoptosis after IR,
we analyzed annexin V positivity at 1 hr, 12 hr, and 24 hr
post-IR. In luminal compartment, we observed a trend of
increasing apoptosis after IR and a significant increase of
apoptosis at the 24 hr time point as compared to non-IR,
whereas MaSCs and basal cells maintained a level of
apoptosis similar to that observed in untreated mice at all
the different time points (Figure 1C). These data suggest
that MaSCs and basal cells are also more resistant to DNA
damage-induced apoptosis. To rule out the possibility
that the enzymatic dissociation of mammary tissue specif-
ically damaged luminal cells, we performed tissue immu-
nofluorescence (IF) staining with cleaved caspase-3 (CC3)
antibody in combination with the myoepithelial cell
marker smooth muscle actin (SMA) or the luminal cell
marker keratin 8 (K8). A similar difference in apoptosis
was observed by direct tissue staining as compared to
flow cytometry analysis. As shown in Figures S2A–S2Q,
luminal cells contained more CC3-positive cells before IR
as compared to myoepithelial cells, and after IR, only
luminal cells exhibited increased apoptosis.
To determine the difference of protein levels in different
subpopulations, MECs were sorted followed by reverse
phase protein array (RPPA) analysis (Figures S1A and S1B).
Consistent with the results from annexin V staining,
RPPA analysis showed that, before IR, pro-apoptotic pro-
teins, including BAX, caspase-3, and caspase-7, were signif-
icantly decreased in MaSCs and basal cells as compared to
luminal cells, whereas no differences were observed in
these protein levels betweenMaSCs and basal cells (Figures
1D and 1E). After IR, BAD and caspase-3 were further down-
regulated in MaSCs, indicating stem cells are more pro-
tected from apoptosis following DNA damage (Figure 1F).
Conversely, RPPA showed an upregulation of BAX in the
luminal compartment after IR, which corresponded with
their increased level of apoptosis (data not shown). These
data were confirmed by western blot analysis as shown in
Figure 1G. Furthermore, in the absence of IR, stress-respon-
sive proteins, such as phospho-p38 (p-p38), phospho-p44
(p-p44), and phospho-AKT (p-AKT), were increased in
MaSCs and basal cells as compared to luminal cells (Figures
S2R–S2T), corresponding with their enhanced survival.
Wild-Type MaSCs Exhibited Increased G2 Arrest after
DNA Damage
Regulation of cell-cycle progression may play a central role
in DDR (Zhou and Elledge, 2000). To elucidate the effects
of DNA damage on cell cycle in different subpopulations,
we fixed and permeabilized freshly dissociated MECs after
surface marker staining, stained the cells with propidium
iodide (PI), and performed flow cytometry analysis (Fig-
ure S1A). Before IR, the majority of cells from all three sub-
populations were in the G0/G1 phase of cell cycle, whereasReports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Authors 379
Figure 1. MaSCs and Basal Cells Are More Resistant to DNA-Damage-Induced Apoptosis
(A) Representative FACS plots of annexin V and Sytox Red staining in different subpopulations 24 hr after IR.
(B) MaSCs and basal cells exhibit significantly decreased apoptosis as compared to luminal cells before IR (data are shown as mean ± SEM;
n = 7; ***p < 0.001; ns, non-significant).
(C) Percentage of annexin-V-positive cells in different subpopulations at different time points (data are shown as mean ± SEM; nonIR and
24 hr, n = 7; 1 hr and 12 hr, n = 4; *p < 0.05).
(D and E) RPPA analysis shows that pro-apoptotic proteins are downregulated in MaSCs and basal cells as compared to luminal cells before
IR (n = 3).
(F) After IR, BAD and caspase-3 were further downregulated in MaSCs (n = 3).
(G) Western blot analysis of BAX and caspase-3 levels in different subpopulations before and 24 hr after IR.a small, but not significantly higher, proportion of MaSCs
resided in the G2/M phase as compared to basal and
luminal cells (Figure 2A). Twelve hours after IR, the percent-
age of cells in the G2/M phase was increased more than
2-fold in MaSCs (Figures 2B and 2E) but began to decrease
by 24 hr post-IR treatment (data not shown). In contrast,
the basal and luminal cells exhibited a similar cell-cycle
status (Figures 2C–2E), indicating that the increased G2
arrest after DNA damage is unique to theMaSC population.
We next investigated the quiescence and proliferation
status of these three cell populations by staining of Ki67,
which is absent in the G0 and present in the interphase
(G1-S-G2/M) of cell cycle (Scholzen and Gerdes, 2000).380 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The ASimilar to the PI staining protocol, we used permeabilized
cells with surfacemarker staining, followed by intracellular
staining. This technique permitted the analysis of prolifer-
ation in the infrequent MaSCs (Figure S1A). In the total
MECs after IR, as shown in Figure 2F, we observed a trend
of a decrease in the percentage of Ki67-positive cells, indi-
cating the presence of DNA-damage-induced quiescence
in the wild-type mammary epithelium. We then analyzed
the proliferation rate in each subpopulation. Before IR,
we observed a trend toward decreased proliferation in
MaSCs as compared to basal and luminal cells (Figure 2G),
whereas after IR, the number of Ki67-positive cells was
slightly increased in MaSCs and decreased significantlyuthors
Figure 2. Wild-Type MaSCs Exhibit Increased G2 Arrest and Evade Damage-Induced Quiescence after IR
(A) Cell-cycle distributions of different subpopulations from MECs before IR were examined using PI staining (data are represented as
mean ± SEM; n = 5).
(B) A significant increase of cells in G2/M was observed in MaSCs 12 hr after IR (data are shown as mean ± SEM; n = 3; **p < 0.01;
*p < 0.05).
(C and D) The cell-cycle profiles of basal and luminal compartments before and 12 hr after IR (data are shown as mean ± SEM; n = 3).
(E) The fold change of cells in G2/M phase 12 hr after IR as compared to non-IR samples (data are shown as mean ± SEM; n = 3; **p < 0.01).
(F) Percentage of Ki67-positive MECs before and after IR (data are shown as mean ± SEM; n = 3).
(G) Representative FACS plots of Ki67 in different subpopulations before and after IR.
(H) Quantification of Ki67 positivity shows that basal and luminal cells became significantly more quiescent after IR (data are shown as
mean ± SEM; n = 3; ***p < 0.001; *p < 0.05).in the other two compartments (Figures 2G and 2H).
These data suggest that basal and luminal cells undergo
damage-induced quiescence after IR, whereas more stem
cells entered interphase from G0, possibly to initiate
a damage-induced injury response to maintain tissue
homeostasis.
Wild-Type MaSCs and Basal Cells Exhibited Increased
NHEJ Activity
Another key process regulated by DDR, other than cell
cycle and apoptosis, is the repair of DNA damage. In mam-
mary glands, the repair efficiency among different epi-
thelial cell populations is still largely unknown. For this
study, phospho-Histone H2AX (Ser139) (gH2AX) was
employed as a marker of DSBs, and gH2AX intracellular
staining was performed on freshly prepared MECs in com-
bination with CD49f and CD24 staining, followed by flow
cytometry analysis (Figure S1A). As shown in Figures 3AStem Celland 3B, 30 min after IR, more than 90% of the cells from
each subpopulation were gH2AX positive, indicating IR in-
duces DSBs in the majority of cells. By 12 hr post-IR treat-
ment, most of the damage was repaired in all three popula-
tions. Slightly less gH2AX staining was observed in MaSCs
after 12 hr as compared to luminal cells; however, this dif-
ference was not statistically significant (Figure 3B). Overall,
these results suggest that all three subpopulations from
wild-type glands exhibit a similar efficiency of DSB repair.
Because most of the MECs were residing in the G0/G1
phase, indicating they mainly use NHEJ to repair DSBs
(Rothkamm et al., 2003), we then analyzed the NHEJ ac-
tivity in each subpopulation of MECs. Using an ex vivo
high-throughput NHEJ assay, we quantified the NHEJ ac-
tivity by measuring the repair of an enzymatically cleaved
GFP reporter. The cells were also electroporated with a
linearized tdtomato plasmid as an internal transfection
efficiency control (Figure 3C). By measuring the numberReports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Authors 381
Figure 3. Wild-Type Basal/MaSC Compartment Exhibits Increased NHEJ Activity
(A) Representative FACS plots of gH2AX intracellular staining 0.5 and 12 hr after IR in different subpopulations.
(B) All three subpopulations exhibit similar DSB repair efficiency (data are shown as mean ± SEM; n = 3).
(C) A schematic depiction of the high-throughput NHEJ assay.
(D) NHEJ activity was significantly higher in the basal/MaSC compartment as compared to luminal cells (data are shown as mean ± SEM;
n = 4; *p < 0.05).
(E) Western blot analysis shows a 1.5-fold increase of 53BP1 level in basal cells as compared to luminal cells.of GFP-positive cells within the tdtomato-positive cell
population, we showed that the basal/MaSC population
(LinCD24+CD29high) exhibits a significantly increased
NHEJ activity as compared to luminal cells (LinCD24+
CD29low; Figure 3D). We also observed an increased level
(1.5-fold) of 53BP1 in basal cells as compared to luminal382 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Acells using western blot analysis (Figure 3E). Whereas
this difference alone may not affect NHEJ activity directly,
it may facilitate the potential of cells to utilize NHEJ,
because 53BP1 is an important positive regulator of
NHEJ pathway (Escribano-Dı´az et al., 2013; Gupta et al.,
2014).uthors
Figure 4. Loss of p53 Disrupts G1 Cell-cycle Arrest and DSB Repair Efficiency in MECs
(A) Cell-cycle distributions of different subpopulations from p53-null MECs before IR (data are represented as mean ± SEM; n = 4;
**p < 0.01).
(B–D) All three subpopulations exhibit higher percentage of G2/M and lower percentage of G1 12 hr after IR (data are represented as
mean ± SEM; n = 3; ***p < 0.001).
(E) Representative FACS plots of gH2AX staining 0.5 and 12 hr after IR in wild-type and p53-null MECs.
(F) Percentage of gH2AX-positive cells in wild-type and p53-null MECs before and after IR (data are shown as mean ± SEM; n = 3;
**p < 0.01).
(G) The decreased repair efficiency was observed in all three subpopulations from p53-null MECs (data are shown as mean ± SEM; 0.5 hr,
n = 1; non-IR and 12 hr, n = 3).Loss of p53 Disrupted G1 Cell Cycle Arrest,
Damage-Induced Quiescence, and DSB Repair
Efficiency in MECs
To study the effects of loss of p53 on DDR in mammary
epithelium, we analyzed the levels of apoptosis, cell-cycle
regulation, and DNA repair mechanisms in MECs isolated
from p53-null mice with and without IR. Surprisingly, the
apoptosis rate in p53-null MECs was similar to that in
wild-type MECs, indicating p53-independent apoptotic
pathways play an important role in mammary epithe-
lium. Similar to wild-type (see Figure 1B), p53-null MaSCs
and basal cells had lower rates of apoptosis before and af-
ter IR as compared to luminal cells, and only the luminal
cells showed increased apoptosis in response to IR (Figures
S3A and S3B). In addition, p53-null MECs exhibited cell-Stem Cellcycle profiles similar to those of wild-type MECs. How-
ever, the difference in the G2/M phase between MaSCs
and the other cell types was more significant (Figure 4A).
Strikingly, after IR, we observed a dramatic increase in the
percentage of cells in the G2/M phase in all three subpop-
ulations, accompanied by a decreased percentage of cells
in the G1 phase (Figures 4B–4D). This result suggests
that loss of p53 impairs G1 arrest in the mammary epithe-
lium, but no effect was observed on G2 arrest, as has been
shown in other cell types (Kuerbitz et al., 1992; Wahl
et al., 1996). On the other hand, total MECs from p53-
null mammary glands after IR treatment exhibited the
same ratio of Ki67-positive cells as compared to their
non-IR counterparts (Figure S3C), indicating that loss of
p53 impairs the damage-induced quiescence observed inReports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Authors 383
Figure 5. TICs Exhibit Decreased
Apoptosis as Compared to Non-TICs
(A) Representative images of CC3 staining in
TICs and non-TICs before and 24 hr after IR
(bars, 10 mm).
(B) TICs exhibited significantly decreased
apoptosis before and after IR (data are
shown as mean ± SEM; n = 3; *p < 0.05).
(C) Western blot analysis shows that, before
IR, p-AKT and p-p38 were upregulated in
TICs as compared to non-TICs.wild-type mammary epithelium. This phenomenon was
seen in all three subpopulations, and p53-null MaSCs
exhibited an increased Ki67 positivity after IR, similar to
what was observed in wild-type MaSCs (Figure S3D).
Previous studies have shown that p53 deficiency results
in delayed DNA repair in cell lines (Zheng et al., 2014).
However, it is still unclear whether loss of p53 affects the
DNA repair efficiency in the mammary gland. Using the
same gH2AX intracellular staining strategy as above (Fig-
ure S1A), we observed that the proportion of gH2AX-posi-
tive cells was significantly higher in p53-null MECs as
compared to wild-type MECs 12 hr after IR, suggesting
that the repair of DSBs is delayed in the absence of p53
(Figures 4E and 4F). A slight increase of gH2AX-positive
staining was also observed in non-IR p53-null MECs, indi-
cating there were more unrepaired DSBs accumulated in
cells even without IR (Figure 4F). Furthermore, the delay
inDSB repair was universal in all three subpopulations (Fig-
ure 4G). Using the high-throughput NHEJ assay to study
the DSB repair mechanisms in p53-null MECs, we demon-
strated that loss of p53 didn’t affect NHEJ activity in the
mammary epithelium (Figure S3E). This result suggests
that the delay in DSB repair in p53-null epithelium is not
due to alterations in NHEJ activity. Overall, the data from
p53-null mammary epithelium indicate that loss of p53
affects cell-cycle regulation and DSB repair efficiency,
which may lead to increased accumulation of mutations
and tumorigenesis.
TICs Exhibited Increased Resistance to Apoptosis as
Compared to Non-TICs
To further understand how transformed p53-null MECs
react to DNA damage, we used T7 tumors from the
p53-null syngeneic mouse model. Previously, we demon-
strated that TICs from T7 tumors are more resistant to IR
(Zhang et al., 2008). Here, we studied the physiological
and molecular mechanisms underlying this resistance.384 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The AAfter dissociation, followed by CD24, CD29, and lineage
marker staining, TICs and non-TICs can be enriched in
LinCD29+CD24high and LinCD29CD24low subpopu-
lations, respectively (Figures S4A and S4B). To investigate
the difference in apoptosis between TICs and non-TICs,
we performed CC3 IF staining instead of annexin V
staining, because we observed false-positive annexin V
staining in the tumor cells, which had been reported pre-
viously to occur in solid tumors (Pozarowski et al., 2003).
After sorting and CC3 staining, we observed significantly
decreased apoptosis in TICs both before and after
IR treatment as compared to non-TICs (Figures 5A and
5B). Interestingly, IR didn’t induce apoptosis in either
subpopulation. We confirmed this result with the TdT-
mediated dUTP nick end labeling (TUNEL) assay, in
which we observed a similar pattern of apoptosis be-
tween TICs and non-TICs (Figure S5). Using western
blot analysis, we observed that there were no differences
in the levels of BAX and caspase-3 between the tumor
subpopulations (data not shown). However, increased
levels of p-AKT and p-p38 were observed in TICs (Fig-
ure 5C), which likely contribute to their enhanced
survival.
p53-Null Tumor Cells Are Highly Proliferative and
Exhibit Improper Cell Cycle Regulation after IR
To investigate IR-induced alterations in cell-cycle regula-
tion in p53-null tumors, PI staining was performed on
the fixed cells with surface marker staining (Figure S4A).
Before IR, there was no significant difference in the cell-
cycle profiles between TICs and non-TICs, although we
observed a slightly higher percentage of TICs residing in
the G2/M phase (Figure 6A), similar to our observation in
MaSCs. At three different time points after IR (0.5 hr,
12 hr, and 24 hr), both TICs and non-TICs exhibited very
similar cell-cycle distributions as compared to their non-
IR counterparts (Figures 6B and 6C; data not shown),uthors
Figure 6. p53-Null Tumor Cells Are Highly Proliferative and Fail to Exhibit Proper Cell-cycle Regulation after IR
(A) Cell-cycle distribution of TICs and non-TICs before IR (data are shown as mean ± SEM; n = 4).
(B and C) Twelve hours after IR, both subpopulations exhibit similar cell-cycle profiles as compared to their non-IR counterparts (data are
shown as mean ± SEM; n = 4).
(D) Representative FACS plots of Ki67 staining in total tumor cells, TICs, and non-TICs before and after IR.
(E) Percentage of Ki67-positive cells in total tumor cells before and after IR (data are shown as mean ± SEM; n = 3).
(F) Percentage of Ki67-positive cells in TICs and non-TICs before and after IR (data are shown as mean ± SEM; n = 3; *p < 0.05; **p < 0.01).indicating that cell-cycle arrest after DNA damage was dis-
rupted in both subpopulations. Similar to the lack of cell-
cycle arrest, p53-null tumor cells also failed to undergo
damage-induced quiescence. As shown in Figures 6D and
6E, total tumor cells were highly proliferative, and the pro-
liferation rates were unaffected byDNAdamage at any time
point after IR. Within the tumors, TICs exhibited a signifi-
cantly higher proliferation rate as compared to non-TICs,
and IR didn’t induce quiescence in either subpopulation
(Figures 6D and 6F). Twenty-four hours after IR, we
observed a slight increase of proliferation in TICs (Fig-
ure 6F), which was similar to our observation in MaSCs.
These data indicate that p53-null tumor cells exhibit not
only impaired G1 and G2 arrest but also disrupted dam-
age-induced quiescence.Stem CellTICs Exhibited More-Rapid DSB Repair and Increased
NHEJ Activity as Compared to Non-TICs
To study the DSB repair efficiency in p53-null tumors, we
sorted forTICsandnon-TICs andperformedgH2AXIF stain-
ing. Similar to the results fromMECs, more than 90% of the
cells exhibited gH2AX foci 0.5 hr after IR, demonstrating
that DSBs occurred in the majority of cells. Twenty-four
hours after IR, less than 25% of TICs showed gH2AX foci,
whereas nearly 40% of non-TICs showed gH2AX foci, sug-
gesting that TICs have the capacity for significantly faster
DSB repair as compared to non-TICs (Figures 7A and 7B).
To confirm this result, we performed a neutral comet assay
to quantify DSBs by measuring the percentage of DNA
in the comet tails. Similar to our observations in gH2AX
IF staining, immediately after IR, there was a significantReports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Authors 385
Figure 7. TICs Exhibit More-Rapid DSB Repair and Increased NHEJ Activity as Compared to Non-TICs
(A) gH2AX IF staining shows that TICs exhibited less damage foci as compared to non-TICs 24 hr after IR (bars, 10 mm).
(B) Percentage of gH2AX-positive cells in TICs and non-TICs before and after IR (data are shown as mean ± SEM; n = 4; **p < 0.01).
(C) Representative images from the neutral comet assay. Comet tails represent damaged DNA (bars, 25 mm).
(D) Percentage of DNA in the comet tails in TICs and non-TICs at different time points of IR treatment (data are shown as mean ± SEM;
70–100 cells were measured in each group; **p < 0.01; *p < 0.05).
(E) NHEJ activity is significantly higher in TICs as compared to non-TICs (data are shown as mean ± SEM; n = 5; **p < 0.01).
(F) Western blot analysis shows that 53BP1 and Ku80 were upregulated in TICs as compared to non-TICs.increase in DSBs in both subpopulations; however, by 24 hr
after IR, TICs showedDSB levels similar to theirnon-IRcoun-
terparts,whereas non-TICs still had significantly higherDSB
levels, suggesting TICs are able to repair the DNA damage
faster (Figures 7C and 7D). To investigate the mechanisms
of DSB repair in tumor cells, we performed the high-
throughput NHEJ assay on freshly digested tumor cells. We
observed a significant increase in NHEJ activity in TICs as
compared to non-TICs (Figure 7E). Using western blot anal-
ysis,weobserved that the levelof53BP1was increasednearly
20%andKu80, a crucial regulator inNHEJpathway (Grundy
et al., 2014), was increased nearly 40% in TICs as compared
to non-TICs (Figure 7F). These endogenous protein levels
may reflect the NHEJ potential in TICs.DISCUSSION
Formore than three decades, p53hasbeenwell studied in its
roles of DDR and tumorigenesis. However, in themammary386 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Agland, it is still largely unknownhow loss of p53 affectsDDR
invivoandhowit leads tomammary tumorigenesis. Inaddi-
tion, the DDR in MaSCs has been difficult to study in vivo
mainly because of their low frequency. In culture systems,
it has been shown that MaSCs and mammary progenitor
cells are more resistant to DNA damage due to upregulation
of p21 andWNTsignaling, respectively (Insinga et al., 2013;
Woodward et al., 2007). However, it is still largely unknown
how MaSCs react to DNA damage in vivo within the intact
microenvironment and their appropriate niche. In this
study, we investigated the mechanisms of DDR, including
apoptosis, cell- cycle regulation, DSB repair, and gene
expression, in different epithelial subpopulations from
wild-type and p53-null mammary glands and p53-null
mammary tumors. First, we demonstrated that, inwild-type
MECs, MaSCs and basal cells exhibited significantly
decreased apoptosis and increased NHEJ activity as com-
pared to luminal cells, possibly due to downregulation of
pro-apoptotic proteins, such as BAX and caspase-3, and up-
regulation of theNHEJ-regulating protein 53BP1.Wild-typeuthors
MaSCs also exhibited increased G2 arrest after IR, accompa-
nied by an increased number of cells entering interphase.
Second, we showed that loss of p53 in MECs impaired G1
cell-cycle arrest, damage-induced quiescence, and DNA
repair efficiency; however, p53-null MaSCs still exhibited
decreased apoptosis. Lastly, we demonstrated that, in p53-
null tumors, TICs were more resistant to apoptosis and
they repaired DSBsmore rapidly with increased NHEJ activ-
ity; however, they failed to exhibit the usual cell-cycle arrest
and quiescence after DNA damage.
In the epidermis and gastrointestinal epithelium, tissue
stem cells have been reported to exhibit differential sensi-
tivity to IR-induced cell death (Barker et al., 2007; Inomata
et al., 2009; Potten et al., 1997), and this sensitivity was
not necessarily related to cell proliferation (Sotiropoulou
et al., 2010). Here, we provide evidence that, in the mam-
mary epithelium, MaSCs are more resistant to IR-induced
apoptosis, even though they exhibit decreased quiescence
after IR. Interestingly, we observed levels of apoptosis
in p53-null MEC subpopulations similar to those in
their wild-type MEC counterparts, indicating that p53-in-
dependent apoptosis plays a more-important role in the
mammary gland. These results correspond with an earlier
observation that apoptosis is not dependent on p53 during
mammary gland ductal morphogenesis and instead might
be regulated by members of the Bcl-2 family (Humphreys
et al., 1996). Similar to MaSCs, TICs exhibited decreased
apoptosis as compared to non-TICs, even though they are
more proliferative. Notably, IR didn’t increase apoptosis
in either subpopulation within the p53-null tumors, indi-
cating that p53 is important for IR-induced apoptosis in
mammary tumors.
The cycling and quiescence ofMaSCs has been especially
difficult to study (Visvader and Stingl, 2014). It has been
shown that long-lived, label-retaining cells are enriched
in the MaSC/basal compartment, indicating they are
slowly dividing (Shackleton et al., 2006). However, it is still
unclear how DNA damage affects the cycling and quies-
cence properties of MaSCs. In our study, we observed a
slightly lower proliferation rate in wild-type MaSCs before
IR as compared to other subpopulations. Interestingly, after
IR, there was an increase in Ki67-positive cells in MaSCs
and TICs, indicating more cells were entering the cell cycle
from G0 into interphase. These data suggest that stem cells
enter the cell cycle to initiate wound repair in the mam-
mary gland and tumors to maintain tissue homeostasis,
similar to what has been observed previously in stem cells
in epidermis and bladder cancers (Kurtova et al., 2015;Mas-
cre´ et al., 2012). In addition, we observed that non-stem
cells in p53-null MECs and tumors failed to induce quies-
cence after IR, indicating that p53 regulates, at least
partially, quiescence in the mammary gland. This result is
supported by previous studies in the hematopoietic systemStem Cell(Asai et al., 2012; Liu et al., 2009). Moreover, previously it
has been shown that a higher percentage of wild-type
MaSCs reside in G2/M phase as compared to other com-
partments (Prater et al., 2014). In this study, we also
observed this phenomenon not only in wild-type MaSCs
but also in p53-null MaSCs and TICs, indicating that
stem cells may be primed for rapid cell division tomaintain
tissue homeostasis.
DSB repair in hair follicle bulge stem cells, hematopoietic
stem cells, and glioma stem cells has been shown to bemore
rapid than in other cell types in their respective tissues (Bao
et al., 2006; Mohrin et al., 2010; Sotiropoulou et al., 2010).
In the present study, however, we didn’t observe increased
efficiency of DSB repair in MaSCs. It’s possible that, by
12hr after IR, all three subpopulationshave already repaired
most of the IR-induced damage, as we observed similar
levels of gH2AX positivity at the 12 and 24 hr post-IR
time points. However, it is technically difficult to investi-
gate shorter time points in these in vivo experiments.
Nevertheless, we observed increased NHEJ activity in
basal/MaSC compartment, which may help facilitate repair
immediately after DNA damage, thereby ensuring genome
integrity. On the other hand, p53 has been linked directly
to DSB repair activity by regulating the HR or NHEJ path-
ways in in vitro studies (Marmorstein et al., 1998; Stu¨rz-
becher et al., 1996; Tang et al., 1999). Although in this study
we didn’t observe a decrease in NHEJ activity in p53-null
MECs, we showed that the repair of DSB was significantly
slower in p53-null MECs as compared to wild-type MECs.
This result suggests that p53-null cells may accumulate mu-
tations more easily after DNA damage in vivo.
With respect to specific DSB repair mechanisms in the T7
p53-null tumor model, we demonstrated that TICs ex-
hibited significantly higher NHEJ activity, contributing to
their faster repair, as compared to non-TICs. However, the
repair kinetics of TICs appeared much slower than normal
MaSCs, which repaired most of the DSBs by 12 hr post-IR.
In addition, a high percentage of p53-null tumor cells were
actively cycling even following DNA damage. These obser-
vations suggest that, once damage occurs, p53-null tumor
cells have an increase probability to accumulate mutations
as compared to MECs. Finally, the increased activity of the
NHEJ repair pathway inMaSCs and TICsmight be a double-
edged sword because NHEJ is an error-prone repair mecha-
nism (Khanna and Jackson, 2001) and might, therefore,
allow more mutations to accumulate over time (Mohrin
et al., 2010).
In this study, we used three models to provide insight
into the variations in the DDR from the normal mammary
gland to breast cancer. First, we studied the DDR in nor-
mal and p53-null mammary glands from pubertal mice,
which is the age when the mammary gland has a higher
susceptibility to tumorigenesis after IR (Castiglioni et al.,Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Authors 387
2007; Land et al., 1980; Preston et al., 2002; Tang et al.,
2014). We showed that loss of p53 in MECs interrupts
DSB repair and cell-cycle regulation after IR, which poten-
tiallymay increase the accumulation ofmutations inmam-
mary epithelium. Second, we used the T7 p53-null tumor
model, which is histologically similar to human basal-like
breast cancer (Zhang et al., 2008) and demonstrated that
T7 TICs repaired DSBmore rapidly with increased NHEJ ac-
tivity and exhibited decreased apoptotic cell death, most
likely contributing to their resistance to IR. These results
may have important implications for designing targeting
therapies to selectively sensitize TICs to radiation or
chemotherapy by treating basal-like tumorswith inhibitors
of cell survival or NHEJ pathways.EXPERIMENTAL PROCEDURES
Mice and Treatment
Wild-type Balb/c female mice were used for the MEC study (5 to
6 weeks old) and tumor transplantation (3 to 4 weeks old). Balb/c
p53-null mice were generously provided by Dr. Xiang Zhang at
Baylor College of Medicine. All animal protocols were reviewed
and approved by the Animal Protocol ReviewCommittee at Baylor
College of Medicine. For IR treatment, a 137Cs irradiator, unit GC-
40 SN 192 (MDS Nordion), was used to irradiate the mice at room
temperature. A single dose of 6 Gy was given.
Primary MEC Preparation
The primary MECs were isolated as previously described (Roarty
et al., 2015). The third, fourth, and fifth pairs of mammary glands
were harvested from 5- to 6-week-old wild-type or p53-null virgin
female mice and minced into small pieces. DMEM/F12 containing
2 mg/ml collagenase A (Roche) was used to digest the glands for
1 hr at 37Cwith constant rotation at 125 rpm. After digestion, or-
ganoids were centrifuged at 1,500 rpm for 5min, followed by three
short washes (1,500 rpm for 7 s) in PBS. The enriched organoids
were then treatedwith 0.25% trypsin at 37C for 5min and filtered
through 40-mm cell strainer, followed by one additional wash in
PBS before labeling with antibodies.
Tumor Transplantation into the Cleared Mammary
Fat Pads
Clearance of host mammary epithelial cells and transplantation
procedures were performed as previously described (Medina,
1996). To generate fresh tumors, diced T7 tumor pieces (<1 mm3)
were transplanted into cleared fat pad of the fourth mammary
glands from 3-week-old Balb/c females. Tumors were allowed to
grow for around 3 weeks and collected when the size reached
0.5–1 cm in diameter.
Primary Tumor Cell Preparation
The primary tumor cells were prepared as previous described
(Zhang et al., 2008). Briefly, tumors were minced into small
pieces and digested in DMEM/F12 containing collagenase type 3
(225 units/ml; Worthington) for 2 hr at 37C with constant rota-388 Stem Cell Reports j Vol. 5 j 378–391 j September 8, 2015 j ª2015 The Ation at 125 rpm. After digestion, cells were first filtered through
70-mm cell strainer, centrifuged at 800 rpm and 1,500 rpm, respec-
tively. The enriched cells were then filtered through 40-mm cell
strainer to obtain single tumor cells and washed three times in
HBSS before antibody labeling.
FACS Staining and Analysis
After primary MEC or tumor cell preparation, lineage-positive cells
were depleted using either the EasySep Mouse Mammary Stem
Cell Enrichment Kit (STEMCELL Technologies; 19758) or Biotin
Mouse Lineage Panel (BD Biosciences; 559971) plus CD140a
(eBioscience; 13-1401-82) and CD31 (BD Biosciences; 553371) anti-
bodies. Cells were then resuspended at a concentration of 107 cells/
ml inHBSS+ (HBSS containing2%FBSwith10mMHEPESbuffer) for
surface marker staining. All antibody incubations were performed
either on ice for 30 min or at room temperature for 20 min. Anti-
mouse antibodies used for surface marker staining include CD49f-
FITC (1:100; BioLegend; 313606), CD49f-Pacific Blue (1:100;
BioLegend; 313620), CD29-FITC (1:100; BioLegend; 102206),
CD29-Pacific Blue (1:100; BioLegend; 102224), CD24-PE (1:100;
BD Biosciences; 553262), CD24-Pacific Blue (1:100; BioLegend;
101820),andCD24-PE/Cy7 (1:100;BioLegend;101821).For sorting,
cells were also stained for Sytox Red (Life Technologies; S34859)
fordead-cell depletion.For annexinVconjugation, cellswithsurface
marker staining were resuspended in 100 ml of annexin-binding
buffer andstainedwith5ml annexinV-AlexaFluor350 (LifeTechnol-
ogies; A23202) for 15 min, followed by Sytox Red staining. For
intracellulargH2AXandKi67 analysis, after surfacemarker staining,
cells were stained with LIVE/DEAD Fixable Dead Cell Stain Kit (Life
Technologies; L10120) before fixed and permeabilized with Tran-
scription Factor (TF) Buffer Set (BD Biosciences; 562574). After fixa-
tion andpermeabilization, cellswere stainedwithanti-mouseH2AX
(pS139)-Alexa Fluor 488 (5 ml/million cells; BDBiosciences; 560445)
or Anti-Mouse Ki67-PE (1:200; eBioscience; 12-5698) at room tem-
perature for 1 hr. For cell-cycle analysis, the cells were fixed with
TF Buffer Set and then treated with PI (50 mg/ml; Sigma) and RNase
A (100 mg/ml; Sigma) for 30min at room temperature. All sorting ex-
periments were done with BD AriaII sorter, and all flow cytometry
analyses were done with BD LSRFortessa cell analyzer. Gating was
based on isotype and single color controls. All FACS data were pro-
cessed and analyzed using FlowJo.
Neutral Comet Assay
The neutral comet assay was performed by following themanufac-
turer’s protocol (Trevigen). Briefly, sorted cells were fixed in low-
melting agarose gel, followed by lysis and electrophoresis. DNA
was visualizedwith SYBR green staining, and imageswere analyzed
with CometScore software.
High-Throughput NHEJ Assay
The pcDNA3-eGFP plasmid was digested with BamHI, which
cleaved between promoter and open reading frame. The pCMV-
tdtomato plasmid was linearized with NotI as an efficiency
control. Two million freshly prepared MECs or tumor cells were
co-electroporated with 5 mg of both linear plasmids using Nucleo-
fectormachine andHumanMammary Epithelial Cell Nucleofector
Kit (Lonza). The cells were then cultured in PMEC mediumuthors
(DMEM/F12 containing 5% FBS, 5 mg/ml insulin, and 10 ng/ml
EGF) in suspension for 18–24 hr, followed by surface marker stain-
ing and flow cytometry analysis.
Statistical Analysis
The unpaired Student’s t test was utilized for statistical analysis.
Plotted values represent means ± SE. n represents the numbers of
independent experiments. A p value less than 0.05 was considered
statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001).
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